ImmuCell Corp
ICCC
NASDAQ
Biotechnology
$10.05
USD
-0.85 (-7.80%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $100.42M
Volume 92.0K
About ImmuCell Corp
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 73 full-time employees. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
CEO
Mr. Olivier te Boekhorst
HQ
Portland, MAINE, US
Founded
1987
Employees
73
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on ICCC.
Based on Quantli research · SEC filings · as of Q1 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
9.6%
-18.6 pp
Gross Margin (TTM)
42.6%
+9.6 pp
Operating Margin (TTM)
8.4%
+9.2 pp
Net Margin (TTM)
-1.8%
-0.8 pp
ROE (TTM)
-1.9%
-0.9 pp
Free Cash Flow (TTM)
$3.38M
+328.0%
Financial Snapshot
Revenue
$29.93M
+9.6%
YoY
Gross Margin
43%
TTM
+29.2%
YoY
Net Income
$-545,403
-100.7%
YoY
Operating Cash Flow
$4.47M
+195.7%
YoY
Key Statistics
Open
$10.72
Previous Close
$10.90
Day Range
$9.75 - $10.72
52 Week Range
$4.52 - $12.10
Volume
92.0K
Average Volume (10 Days)
20.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$100.42M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
3.35
Price / Book
3.45
Financial Highlights
Profit Margin
-1.8%
Return on Assets
-1.2%
Return on Equity
-1.9%
Revenue (TTM)
$29.93M
Net Income (TTM)
$-545,403
Diluted EPS (TTM)
-$0.06
Total Cash (MRQ)
$6.81M
Levered FCF (TTM)
$3.38M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Similar Stocks
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 11